US 12,458,638 B2
Method of stimulating neutrophil survival and reducing neutropenia
Ramon Mohanlal, New York, NY (US); Lan Huang, New York, NY (US); and George Kenneth Lloyd, San Carlos, CA (US)
Assigned to BeyondSpring Pharmaceuticals, Inc., New York, NY (US)
Filed by BEYONDSPRING PHARMACEUTICALS, INC., New York, NY (US)
Filed on Jul. 29, 2022, as Appl. No. 17/877,198.
Application 17/877,198 is a continuation of application No. 16/482,547, granted, now 11,400,086, previously published as PCT/US2018/016498, filed on Feb. 1, 2018.
Claims priority of provisional application 62/621,533, filed on Jan. 24, 2018.
Claims priority of provisional application 62/453,375, filed on Feb. 1, 2017.
Prior Publication US 2022/0378784 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 31/337 (2006.01); A61K 38/19 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 31/337 (2013.01); A61K 38/193 (2013.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01)] 21 Claims
 
1. A method of treating a chemotherapy induced neutropenia in a subject, comprising co-administering one or more G-CSF compounds and a single dose of plinabulin, wherein the one or more G-CSF drug is administered in the range of 12 hours to 72 hours after the administration of the single dose of plinabulin.
 
15. A method of stimulating neutrophil survival in a subject, comprising co-administering one or more G-CSF compounds and a single dose of plinabulin, wherein the one or more G-CSF drug is administered in the range of 12 hours to 72 hours after the administration of the single dose of plinabulin.